Advanced search
Publication Cover
Leukemia & Lymphoma Volume 59, 2018 - Issue 6
Submit an article Journal homepage
214
Views
0
CrossRef citations to date
0
Altmetric
Letter to the Editor

Role and regulation of microRNAs targeting BTK in acute myelogenous leukemia

Lara RizzottoDepartment of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH, USA; View further author information
,
Tzung-Huei LaiDepartment of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH, USA; View further author information
,
Arianna BottoniDepartment of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH, USA; View further author information
,
Jennifer A. WoyachDepartment of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH, USA; View further author information
,
Rosa LapalombellaDepartment of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH, USA; View further author information
,
Clara D. BloomfieldThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USAView further author information
,
John C. ByrdDepartment of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH, USA; View further author information
&
Deepa SampathDepartment of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH, USA; Correspondence[email protected]
View further author information
 show all
Pages 1461-1465 | Received 19 May 2017, Accepted 30 Aug 2017, Published online: 18 Sep 2017

References

  • Oellerich T, Mohr S, Corso J, et al. FLT3-ITD and TLR9 use Bruton tyrosine kinase to activate distinct transcriptional programs mediating AML cell survival and proliferation. Blood. 2015;125:1936–1947.
  • Rushworth SA, Murray MY, Zaitseva L, et al. Identification of Bruton’s tyrosine kinase as a therapeutic target in acute myeloid leukemia. Blood. 2014;123:1229–1238.
  • Zaitseva L, Murray MY, Shafat MS, et al. Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML. Oncotarget. 2014;5:9930–9938.
  • Cortes J, Estey E, Stein AS, et al. A multicenter, open-label phase 2a study of ibrutinib with or without cytarabine in patients with acute myeloid leukemia (PCYC-1131). J Clin Oncol. 2015;33. (suppl; abstr TPS7096).
  • Wu H, Hu C, Wang A, et al. Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML. Leukemia. 2016;30:754–757.
  • Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136:215–233.
  • Bottoni A, Rizzotto L, Lai TH, et al. Targeting BTK through microRNA in chronic lymphocytic leukemia. Blood. 2016;128:3101–3112.
  • Garcia-Manero G, Yang H, Bueso-Ramos C, et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood. 2008;111:1060–1066.
  • Garcia-Manero G, Tambaro FP, Bekele NB, et al. Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. J Clin Oncol. 2012;30:2204–2210.
  • Quintas-Cardama A, Santos FP, Garcia-Manero G. Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Leukemia. 2011;25:226–235.
  • Evens AM, Balasubramanian S, Vose JM, et al. A phase I/II multicenter, open-label study of the oral histone deacetylase inhibitor abexinostat in relapsed/refractory lymphoma. Clin Cancer Res.2016;22:1059–1066.
  • Raedler LA. Farydak (panobinostat): first HDAC inhibitor approved for patients with relapsed multiple myeloma. Am Health Drug Benefits. 2016;9(Spec Feature): 84–87.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.